
Alzamend Neuro (ALZN) Stock Forecast & Price Target
Alzamend Neuro (ALZN) Analyst Ratings
Bulls say
Alzamend Neuro Inc. has reported positive top-line results from its clinical studies in June 2023, reflecting promising progress in its development of innovative therapies for neurodegenerative diseases and psychiatric disorders. The company's proprietary drug candidates, AL001 and AL002, highlight its commitment to addressing significant unmet medical needs, particularly in Alzheimer's treatment. The current valuation is deemed attractive, with substantial growth potential indicated by net present value analyses, positioning Alzamend Neuro favorably for future investment.
Bears say
Alzamend Neuro Inc has reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which notably deviates from earlier estimates of $(0.69). This significant loss underscores the company's ongoing financial challenges, particularly in achieving profitability amid an early clinical-stage pipeline focused on neurodegenerative diseases. Additionally, the company faces multiple risks, including liquidity concerns, potential failures in clinical trials, regulatory approval hurdles, and competitive pressures, all of which contribute to a negative outlook on its stock performance.
This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.
Alzamend Neuro (ALZN) Analyst Forecast & Price Prediction
Start investing in Alzamend Neuro (ALZN)
Order type
Buy in
Order amount
Est. shares
0 shares